Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F9 | P00740 | 13/20 | 0.43 |
| ▸ | F10 | P00742 | 7/20 | 0.43 |
| ▸ | C1S | P09871 | 2/20 | 0.43 |
| ▸ | CFD | P00746 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.42 |
| ▸ | PLAU | P00749 | 5/20 | 0.42 |
| ▸ | PLG | P00747 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26110187 | 0.79 | GPR35 (0.53) | HDAC6UGT2B7 | |
| Hydrochloric Acid SCHEMBL9431648 | 0.76 | HDAC6 (0.57) | F9F10C1SCFDHDAC6 | |
| Hydrochloric Acid SCHEMBL9432456 | 0.75 | F9 (0.56) | F9F10PLAU | |
| SCHEMBL13709514 | 0.75 | HSD17B1 (0.51) | F9F10C1SCFDHDAC6 | |
| SCHEMBL13709631 | 0.75 | F9 (0.49) | F9F10C1SCFDHDAC6 | |
| SCHEMBL13709506 | 0.73 | F9 (0.47) | F9F10C1SCFDHDAC6 | |
| SCHEMBL13709512 | 0.73 | F9 (0.56) | F9F10C1SCFDHDAC6 | |
| SCHEMBL3504110 | 0.73 | PTPN2 (0.46) | HDAC6UGT2B7 | |
| Hydrochloric Acid SCHEMBL9431276 | 0.72 | PLAU (0.51) | F9F10C1SCFDHDAC6 | |
| SCHEMBL13709655 | 0.72 | CA2 (0.56) | F9F10C1SCFDHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221564-A1 | Heterocyclic Compounds and Their Use in the Treatment of Cardiovascular Disease | TRIGEN LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090221564-A1 | Heterocyclic Compounds and Their Use in the Treatment of Cardiovascular Disease | TRIGEN LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221564-A1 | Heterocyclic Compounds and Their Use in the Treatment of Cardiovascular Disease | F12, F5, F3 | F9 5/4885F10 7/4885C1S 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.